The Janssen RORgt inhibitor, JNJ-61803534, is an oral clinical candidate that was well-tolerated in humans up to 200 mg and demonstrated PD. Unfortunately, development was terminated due to findings in…
Drug Hunter > Molecules > JNJ-61803534
become a member to continue reading
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.
- Stay up-to-date and save more time with exclusive members-only content
- On-board new team members with educational content and case studies
- Generate ideas and discussion with easy-to-read slide decks
- Generate ideas and discussion with easy-to-read slide decks